X4 Pharmaceuticals, Inc. (XFOR)
Pre-Market:
| Previous Close | 1.2300 |
| Open | 1.2600 |
| Bid | 1.2600 x 1300 |
| Ask | 1.3000 x 2500 |
| Day's Range | 1.2200 - 1.2900 |
| 52 Week Range | 0.5720 - 2.5750 |
| Volume | |
| Avg. Volume | 2,458,927 |
| Market Cap | 216.64M |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5700 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.55 |
Simply Wall St.X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns
Key Insights Institutions' substantial holdings in X4 Pharmaceuticals implies that they have significant influence over...
GlobeNewswireX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 1, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee
- GlobeNewswire
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming Needham 23rd Annual Healthcare Conference being held virtually from April 8-11, 2024, and the Piper Sandler Spring Biopharma Symposium being held in Boston from April 16-17, 2024. Needham 23rd Annual Healthcare Conference Date: Monday, April 8, 2024 Time: 9:30 AM
